Moderate to Severe Glabellar Lines
13 clinical trials · Condition
◉ Watch Moderate to Severe Glabellar Lines
| Record | Firm | Date |
|---|---|---|
| A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines (NCT05743634) | Chongqing Claruvis Pharmaceutical Co., Ltd. | 2022-03-22 |
| DWP450 for Treating Moderate to Severe Glabellar Lines (NCT06354127) | Daewoong Pharmaceutical Co. LTD. | 2020-08-12 |
| Safety and Efficacy Study of ATGC-100 for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects (NCT03970876) | EuBiologics Co.,Ltd | 2019-04-19 |
| Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines (NCT02353871) | Ipsen | 2015-01-01 |
Track Moderate to Severe Glabellar Lines automatically
Every clearance here is in the API, with alerts when new ones post.